Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
- Status
- COMPLETED
- Phase
- PHASE2
Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Lenalidomide Plus Chemotherapy for AML
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide Maintenance Therapy for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- PHASE2
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
- Status
- TERMINATED
- Phase
- PHASE3
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- NA
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1